Total Payments
$9,612
2024 Payments
$873.46
Companies
11
Transactions
42
Medicare Patients
629
Medicare Billing
$51,521
Payment Breakdown by Category
Consulting$4,800 (49.9%)
Research$2,035 (21.2%)
Food & Beverage$1,561 (16.2%)
Education$962.38 (10.0%)
Other$254.75 (2.7%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $4,800 | 2 | 49.9% |
| Unspecified | $2,035 | 3 | 21.2% |
| Food and Beverage | $1,561 | 32 | 16.2% |
| Education | $962.38 | 4 | 10.0% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $254.75 | 1 | 2.7% |
Payments by Type
General
$7,578
39 transactions
Research
$2,035
3 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $4,800 | 2 | $0 (2022) |
| Novartis Pharmaceuticals Corporation | $1,409 | 6 | $0 (2024) |
| EMD Serono, Inc. | $1,314 | 6 | $0 (2022) |
| Sun Pharmaceutical Industries Inc. | $960.31 | 1 | $0 (2017) |
| Celgene Corporation | $418.04 | 18 | $0 (2024) |
| Carl Zeiss Meditec USA, Inc. | $303.80 | 1 | $0 (2024) |
| GENZYME CORPORATION | $271.25 | 2 | $0 (2024) |
| Novartis Pharma AG | $57.59 | 3 | $0 (2019) |
| ANI Pharmaceuticals, Inc. | $32.18 | 1 | $0 (2023) |
| Amgen Inc. | $27.39 | 1 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $873.46 | 10 | Carl Zeiss Meditec USA, Inc. ($303.80) |
| 2023 | $320.44 | 14 | Celgene Corporation ($288.26) |
| 2022 | $2,683 | 3 | E.R. Squibb & Sons, L.L.C. ($2,400) |
| 2021 | $3,362 | 5 | E.R. Squibb & Sons, L.L.C. ($2,400) |
| 2019 | $545.71 | 3 | NOVARTIS PHARMACEUTICALS CORPORATION ($515.62) |
| 2018 | $67.85 | 2 | Novartis Pharmaceuticals Corporation ($40.35) |
| 2017 | $1,760 | 5 | Sun Pharmaceutical Industries Inc. ($960.31) |
All Payment Transactions
42 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 09/24/2024 | Amgen Inc. | UPLIZNA (Biological) | Food and Beverage | In-kind items and services | $27.39 | General |
| Category: Inflammation/Rare Disease | ||||||
| 09/19/2024 | Novartis Pharmaceuticals Corporation | KESIMPTA (Drug) | Food and Beverage | In-kind items and services | $136.41 | General |
| Category: Neurology | ||||||
| 09/18/2024 | Novartis Pharmaceuticals Corporation | KESIMPTA (Drug) | Food and Beverage | In-kind items and services | $136.38 | General |
| Category: Neurology | ||||||
| 07/31/2024 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $22.44 | General |
| Category: Neuroscience | ||||||
| 06/06/2024 | GENZYME CORPORATION | — | Food and Beverage | In-kind items and services | $146.25 | General |
| 06/04/2024 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $24.36 | General |
| Category: Neuroscience | ||||||
| 04/05/2024 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $25.38 | General |
| Category: Neuroscience | ||||||
| 04/05/2024 | Novartis Pharmaceuticals Corporation | KESIMPTA (Drug) | Food and Beverage | In-kind items and services | $21.80 | General |
| Category: Neurology | ||||||
| 03/26/2024 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $29.25 | General |
| Category: Neuroscience | ||||||
| 01/17/2024 | Carl Zeiss Meditec USA, Inc. | ATLAS 500 (Device) | Food and Beverage | In-kind items and services | $303.80 | General |
| Category: Optical Topographer | ||||||
| 11/06/2023 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $22.72 | General |
| Category: Neuroscience | ||||||
| 11/01/2023 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $21.77 | General |
| Category: Neuroscience | ||||||
| 10/17/2023 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $29.67 | General |
| Category: Neuroscience | ||||||
| 09/06/2023 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $24.95 | General |
| Category: Neuroscience | ||||||
| 08/17/2023 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $20.46 | General |
| Category: Neuroscience | ||||||
| 07/12/2023 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $19.10 | General |
| Category: Neuroscience | ||||||
| 06/13/2023 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $18.69 | General |
| Category: Neuroscience | ||||||
| 05/23/2023 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $33.09 | General |
| Category: Neuroscience | ||||||
| 05/10/2023 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $19.98 | General |
| Category: Neuroscience | ||||||
| 04/14/2023 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $23.27 | General |
| Category: Neuroscience | ||||||
| 03/28/2023 | ANI Pharmaceuticals, Inc. | PURIFIED CORTROPHIN GEL (Drug) | Food and Beverage | In-kind items and services | $32.18 | General |
| Category: Treatment of certain chronic autoimmune disorders, including acute exacerbations of MS and RA | ||||||
| 03/28/2023 | Celgene Corporation | — | Food and Beverage | Cash or cash equivalent | $22.87 | General |
| 02/21/2023 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $12.56 | General |
| Category: Neuroscience | ||||||
| 01/26/2023 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $19.13 | General |
| Category: Neuroscience | ||||||
| 11/15/2022 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $28.35 | General |
| Category: Neuroscience | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| Sun Pharma Research | Sun Pharmaceutical Industries Inc. | $960.31 | 1 |
| RESEARCH RELATED PUBLICATION SUPPORT | NOVARTIS PHARMACEUTICALS CORPORATION | $558.58 | 1 |
| RESEARCH RELATED PUBLICATIONS SUPPORT | NOVARTIS PHARMACEUTICALS CORPORATION | $515.62 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 3 | 154 | 164 | $79,064 | $13,850 |
| 2022 | 2 | 136 | 144 | $60,656 | $10,792 |
| 2021 | 3 | 157 | 174 | $68,768 | $13,851 |
| 2020 | 3 | 182 | 200 | $73,626 | $13,029 |
Total Patients
629
Total Services
682
Medicare Billing
$51,521
Procedure Codes
14
All Medicare Procedures & Services
14 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 74 | 80 | $31,040 | $5,624 | 18.1% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 52 | 55 | $31,460 | $5,285 | 16.8% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 16 | 16 | $11,520 | $2,040 | 17.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 12 | 13 | $5,044 | $901.95 | 17.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 97 | 104 | $40,352 | $7,017 | 17.4% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 25 | 26 | $14,872 | $2,831 | 19.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 14 | 14 | $5,432 | $943.30 | 17.4% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 120 | 135 | $46,832 | $9,183 | 19.6% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 21 | 23 | $10,780 | $2,471 | 22.9% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Facility | 2021 | 16 | 16 | $11,156 | $2,196 | 19.7% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 121 | 138 | $42,988 | $7,644 | 17.8% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 29 | 30 | $13,189 | $2,492 | 18.9% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Facility | 2020 | 21 | 21 | $14,028 | $2,323 | 16.6% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 11 | 11 | $3,421 | $570.42 | 16.7% |
About Dr. John Corboy, MD
Dr. John Corboy, MD is a Neurology healthcare provider based in Aurora, Colorado. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/02/2006. The National Provider Identifier (NPI) number assigned to this provider is 1922045228.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. John Corboy, MD has received a total of $9,612 in payments from pharmaceutical and medical device companies, with $873.46 received in 2024. These payments were reported across 42 transactions from 11 companies. The most common payment nature is "Consulting Fee" ($4,800).
As a Medicare-enrolled provider, Corboy has provided services to 629 Medicare beneficiaries, totaling 682 services with total Medicare billing of $51,521. Data is available for 4 years (2020–2023), covering 14 distinct procedure/service records.
Ad
Practice Information
- Specialty Neurology
- Location Aurora, CO
- Active Since 06/02/2006
- Last Updated 10/02/2012
- Taxonomy Code 2084N0400X
- Entity Type Individual
- NPI Number 1922045228
Products in Payments
- ZEPOSIA (Drug) $2,795
- GILENYA (Drug) $1,115
- Odomzo (Drug) $960.31
- ATLAS 500 (Device) $303.80
- KESIMPTA (Drug) $294.59
- DISEASE STATE (Drug) $125.00
- PURIFIED CORTROPHIN GEL (Drug) $32.18
- FTD_GILENYA_NEUROSCIENCE (Drug) $30.09
- FTY720D (Drug) $27.50
- UPLIZNA (Biological) $27.39
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Neurology Doctors in Aurora
Dr. Enrique Alvarez, Md, Phd, MD, PHD
Neurology — Payments: $632,810
Neurology $632,810
Jeffrey Bennett, Md, MD
Neurology — Payments: $555,924
Neurology $555,924
Timothy Vollmer, Md, MD
Neurology — Payments: $294,911
Neurology $294,911
Julie Parsons, Md, MD
Neurology — Payments: $184,813
Neurology $184,813
Dr. Haley Burke, Md, MD
Neurology — Payments: $175,463
Neurology $175,463
Anna Shah, M.d, M.D
Neurology — Payments: $141,632
Neurology $141,632